Back to Trials
NCT07456878PHASE1Recruiting

Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas

Mayo Clinic

Start Date

1/8/2026

Completion Date

12/1/2026

Summary

The purpose of this research is to evaluate the diagnostic role and clinical efficacy of investigational FET-PET/MRI in detecting MRI-occult primary or residual/recurrent functional pituitary adenomas (PAs) and its influence on clinical and surgical decisions.

Eligibility Criteria

Age Range: 18 years to 75 years

Inclusion Criteria: * Patients 18 to 75 years of age with biochemically proven CD, Acromegaly, or tumor hyperprolactinemia as per current Endocrinology guidelines. * Clinical DCE-MRI protocol that is negative or equivocal for identifiable tumor. * Patient willing to have surgery if lesion found, or already scheduled for surgery and lesion identification would be helpful. * Able to provide informed consent and be capable of completing the imaging protocols. * Female subjects of childbearing potential (women of childbearing potential \[WOCBP\]) must have a negative urine pregnancy test ≤48 hours prior to the 18F-FET injection. Exclusion Criteria: * Patients with contraindications to MRI or PET scans. * Patients with known allergies to contrast agents or other imaging-related materials. * Patients with severe medical conditions that preclude participation in the study (e.g. inability to lie supine for 30-60 minutes). * Patients with successful MRI localization of the adenoma.

Interventions

DRUG

FET-PET/MRI

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Pituitary Adenoma

Locations

Mayo Clinic

Jacksonville, Florida 32224

United States